Lisinopril
Generic Name: Lisinopril
Uses & Medical Indications
Management of essential and secondary hypertension, adjunctive therapy in congestive heart failure with reduced ejection fraction (HFrEF), and reduction of mortality in hemodynamically stable patients within 24 hours of acute myocardial infarction.
Essential Hypertension, Congestive Heart Failure (HFrEF), Post-Myocardial Infarction, Diabetic Nephropathy
Work Mechanism & Pharmacology
Patient Overview of Work Mechanism
Lisinopril blocks the enzyme that causes blood vessels to constrict and narrow. By allowing blood vessels to relax and widen, blood flows smoothly and heart strain is substantially reduced.
Clinical Mechanism of Action (MoA)
Competitive inhibitor of angiotensin-converting enzyme (ACE / kininase II). Prevents conversion of the decapeptide angiotensin I into angiotensin II, a potent vasoconstrictor and stimulator of adrenal aldosterone release. Concurrently reduces bradykinin degradation, promoting systemic vasodilation, reducing peripheral vascular resistance, and reducing cardiac afterload.
Dosage & Administration Guidelines
Hypertension: Start 10 mg orally once daily (or 5 mg if on diuretic). Maintenance: 20 to 40 mg once daily. Heart Failure: Start 2.5 to 5 mg once daily; titrate upward to target 20-35 mg daily.
Children ≥6 years with hypertension: Start 0.07 mg/kg once daily (max initial 5 mg); titrate up to max 40 mg daily.
Start with 2.5 mg to 5 mg once daily; monitor blood pressure and renal function closely.
80 mg once daily (rarely exceeds 40 mg in clinical practice).
eGFR 30-50 mL/min: Start 5 mg/day. eGFR 10-30 mL/min: Start 2.5 mg/day. eGFR <10 mL/min: 2.5 mg on dialysis days.
Lisinopril is not metabolized by the liver; excreted unchanged by the kidneys. No hepatic dose adjustment required.
Side Effects & Safety Warnings
Dry, persistent, non-productive cough (in 5-20% of patients due to bradykinin accumulation), dizziness, hypotension, headache.
Angioedema (swelling of face, lips, tongue, larynx with airway obstruction), severe hyperkalemia, acute renal failure, agranulocytosis.
History of angioedema related to prior ACE inhibitor therapy, hereditary/idiopathic angioedema, pregnancy, co-administration with Aliskiren in diabetes.
Fetal Toxicity: When pregnancy is detected, discontinue Lisinopril as soon as possible; drugs acting on the renin-angiotensin system can cause oligohydramnios, fetal renal agenesis, and death.
Interactions (Drugs, Food & Alcohol)
Spironolactone, Potassium supplements (severe hyperkalemia), NSAIDs (blunted blood pressure control, acute renal failure), Lithium (lithium toxicity).
Can be taken with or without food. Avoid potassium-containing salt substitutes.
Avoid heavy alcohol; compounding vasodilation can trigger severe orthostatic hypotension and syncope.
Identified Clinical Drug Interactions for Lisinopril:
Potentially fatal hyperkalemia (dangerously elevated serum potassium levels).
Blunted antihypertensive efficacy and sharp increase in acute renal hemodynamic impairment.
Pregnancy & Breastfeeding Safety
Strictly contraindicated in the second and third trimesters of pregnancy due to fatal fetal renal damage, calvarial hypoplasia, and skull ossification defects.
Use alternative antihypertensives (such as Enalapril or Captopril) during breastfeeding due to limited clinical data on lisinopril in neonates.
Patient Counseling & Practical Advice
Rise slowly from sitting or lying positions to prevent dizziness. If you develop a persistent dry hacking cough or facial swelling, contact your doctor.
Take as soon as you remember. Skip if it is nearly time for your next scheduled dose. Never take two doses together.
Blood pressure, serum potassium, BUN, serum creatinine baseline and 1-2 weeks post initiation/titration.
Frequently Asked Questions
Related Medicines in Antihypertensive
When to Seek Urgent Medical Attention
Swelling of the tongue, throat, or mouth causing wheezing or inability to breathe (acute angioedema emergency).
Content for Lisinopril was synthesized from standardized public health monographs, official pharmacopoeias, and health authorities:
- AHA / ACC — Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure
- European Society of Cardiology (ESC) — ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
The information provided on this website is for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition.